4//SEC Filing
KAWAS LEEN 4
Accession 0001140361-23-051260
CIK 0001305253other
Filed
Nov 1, 8:00 PM ET
Accepted
Nov 2, 9:14 PM ET
Size
6.7 KB
Accession
0001140361-23-051260
Insider Transaction Report
Form 4
KAWAS LEEN
10% Owner
Transactions
- Purchase
Common Stock
2023-10-31$0.26/sh+12,345$3,228→ 4,391,432 total(indirect: See footnote.) - Purchase
Common Stock
2023-10-31$0.26/sh+11,987$3,147→ 4,379,087 total(indirect: See footnote.)
Footnotes (2)
- [F1]Ms. Kawas controls Propel Bio Management LLC, a Delaware limited liability company ("Propel Management"). Ms. Kawas also shares control of Propel Bio Partners LLC, a Delaware limited liability company ("Propel General Partner"). Ms. Kawas, Propel Management and Propel General Partner act as the investment advisor to, or general partner of, or otherwise provide discretionary advisory services to, one or more private investment funds, and such investment funds acquired the referenced shares of Common Stock.
- [F2]Ms. Kawas expressly disclaims beneficial ownership of the shares of Common Stock reported herein except to the extent of any pecuniary interest.
Documents
Issuer
Eiger BioPharmaceuticals, Inc.
CIK 0001305253
Entity typeother
Related Parties
1- filerCIK 0001822491
Filing Metadata
- Form type
- 4
- Filed
- Nov 1, 8:00 PM ET
- Accepted
- Nov 2, 9:14 PM ET
- Size
- 6.7 KB